Aycan Fahri Erkan

Aycan Fahri Erkan

Auto-generated profile, based on publicly available information

Aycan Fahri Erkan

Department of Cardiology, Faculty of Medicine, Ufuk University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Texas Heart Institute Journal
Verified
Journal Article
Closed access
AEAycan Fahri Erkan
Aycan Fahri Erkan
ATAsli Tanindi
Asli Tanindi
SKSinan Altan Kocaman
Sinan Altan Kocaman
MUMurat Ugurlu
Murat Ugurlu
HTHasan Fehmi Tore
Hasan Fehmi Tore
Epicardial adipose tissue thickness is associated with the severity and extent of atherosclerotic coronary artery disease. We prospectively investigated whether epicardial adipose tissue thickness is related to coronary artery disease extent and complexity as denoted by Gensini and Syntax scores, and whether the thickness predicts critical disease. After performing coronary angiography in 183 patients who had angina or acute myocardial infarction, we divided them into 3 groups: normal coronary arteries, noncritical disease (≥1 coronary lesion with <70% stenosis), and critical disease (≥1 coronary lesion with <70% stenosis). We used transthoracic echocardiography to measure epicardial adipose tissue thickness, then calculated Gensini and Syntax scores by reviewing the angiograms. Mean thicknesses were 4.3 ± 0.9, 5.2 ± 1.5, and 7.5 ± 1.9 mm in patients with normal coronary arteries, noncritical disease, and critical disease, respectively (P <0.001). At progressive thicknesses (7 mm), mean Gensini scores were 4.1 ± 5.5, 19.8 ± 15.6, and 64.9 ± 32.4, and mean Syntax scores were 4.7 ± 5.9, 16.6 ± 8.5, and 31.7 ± 8.7, respectively (both P <0.001). Thickness had strong and positive correlations with both scores (Gensini, r =0.82, P <0.001; and Syntax, r =0.825, P <0.001). The cutoff thickness value to predict critical disease was 5.75 mm (area under the curve, 0.875; 95% confidence interval, 0.825–0.926; P <0.001). Epicardial adipose tissue thickness is independently related to coronary artery disease extent and complexity as denoted by Gensini and Syntax scores, and it predicts critical coronary artery disease.

23 October 2021 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
NCNeslihan Coban
Neslihan Coban
AOAybike Sena Ozuynuk
Aybike Sena Ozuynuk
AEAycan Fahri Erkan
Aycan Fahri Erkan
FGFiliz Guclu-Geyik
Filiz Guclu-Geyik
BEBerkay Ekici
Berkay Ekici

21 December 2013 in Herz
Verified
Journal Article
Closed access
PDF file
AEA.F. Erkan
A.F. Erkan
GBG.K. Beriat
G.K. Beriat
BEB. Ekici
B. Ekici
CDC. Doğan
C. Doğan
SKS. Kocatürk
S. Kocatürk
HTH.F. Töre
H.F. Töre

1 January 2022 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
AOAybike Sena Ozuynuk
Aybike Sena Ozuynuk
AEAycan Fahri Erkan
Aycan Fahri Erkan
NDNazli Dogan
Nazli Dogan
BEBerkay Ekici
Berkay Ekici
NENihan Erginel-Unaltuna
Nihan Erginel-Unaltuna
NCNeslihan Coban
Neslihan Coban

18 July 2013 in Herz
Verified
Journal Article
Closed access
PDF file
AEA. Erkan
A. Erkan
BEB. Ekici
B. Ekici
MUM. Uğurlu
M. Uğurlu
GIG. İş
G. İş
RŞR. Şeker
R. Şeker
ŞKŞ. Korkmaz
Ş. Korkmaz

2 July 2021 in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
Verified
Journal Article
Open access
BEBerkay Ekici
Berkay Ekici
MYMehmet Yaman
Mehmet Yaman
MKMurathan Kucuk
Murathan Kucuk
SDSeckin Dereli
Seckin Dereli
MYMustafa Yenerçağ
Mustafa Yenerçağ
MZMehdi Zoghi
Mehdi Zoghi
Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey. The ARNi-TR is a multicenter, noninterventional, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was initiated at hospitalization or under outpatient clinic control. N-terminal pro-brain natriuretic peptide (NT-proBNP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parameters, p<0.001) within 1-year follow-up. In both groups, a decrease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypertension (16.9%) was the most common side effect in patients using ARN. The ARNi-TR study offers comprehensive real-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proBNP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study.